Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

European Journal of Cancer

Volumn 68, Issue , 2016, Pages 134-147

  de Charette, Marie ^a   Marabelle, Aurélien ^b,c   Houot, Roch ^a,d  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c University Paris XI   (France)

^d INSERM   (France)

Author keywords

Antigen presentation; Cancer; Checkpoint inhibitors; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; CD40 AGONIST; CD86 ANTIGEN; HISTONE DEACETYLASE INHIBITOR; INTERFERON; LENALIDOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN TYROSINE KINASE INHIBITOR; TOLL LIKE RECEPTORS AGONIST; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL TRANSFORMATION; CHEMOSENSITIVITY; DOWN REGULATION; DRUG MECHANISM; HUMAN; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; RADIOTHERAPY; T LYMPHOCYTE; TUMOR ESCAPE;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTINEOPLASTIC AGENTS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RADIOTHERAPY; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84991711222     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.09.010     Document Type: Review

References (136)

1. [1] Ribas, A., Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 5 (2015), 915–919.
2. [2] Hegde, P.S., Karanikas, V., Evers, S., The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res 22 (2016), 1865–1874.
3. [3] Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
4. [4] Heath, W.R., Carbone, F.R., Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 1 (2001), 126–134.
5. [5] Butte, M.J., Keir, M.E., Phamduy, T.B., Sharpe, A.H., Freeman, G.J., Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27 (2007), 111–122.
6. [6] Cycon, K.A., Clements, J.L., Holtz, R., Fuji, H., Murphy, S.P., The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells. Immunology 128 (2009), e641–e651.
7. [7] Tazi, A., Moreau, J., Bergeron, A., Dominique, S., Hance, A.J., Soler, P., Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenvironment. J Immunol 163 (1999), 3511–3515.
8. [8] Seliger, B., Maeurer, M.J., Ferrone, S., Antigen-processing machinery breakdown and tumor growth. Immunol Today 21 (2000), 455–464.
9. [9] Garrido, F., Cabrera, T., Aptsiauri, N., “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127 (2010), 249–256.
10. [10] Kobayashi, K.S., van den Elsen, P.J., NLRC5: a key regulator of MHC class I-dependent immune responses. Nat Rev Immunol 12 (2012), 813–820.
11. [11] Garrido, F., Algarra, I., MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83 (2001), 117–158.
12. [12] Garrido, F., Aptsiauri, N., Doorduijn, E.M., Garcia Lora, A.M., van Hall, T., The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 39 (2016), 44–51.
13. [13] Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., Racanelli, V., MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst 105 (2013), 1172–1187.
14. [14] Yoshihama, S., Roszik, J., Downs, I., Meissner, T.B., Vijayan, S., Chapuy, B., et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci 113 (2016), 5999–6004.
15. [15] Mimura, K., Shiraishi, K., Mueller, A., Izawa, S., Kua, L.-F., So, J., et al. The MAPK pathway is a predominant regulator of HLA—a expression in esophageal and gastric cancer. J Immunol 191 (2013), 6261–6272.
16. [16] Herrmann, F., Lehr, H.-A., Drexler, I., Sutter, G., Hengstler, J., Wollscheid, U., et al. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 64 (2004), 215–220.
17. [17] Reichel, J., Chadburn, A., Rubinstein, P.G., Giulino-Roth, L., Tam, W., Liu, Y., et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 125 (2015), 1061–1072.
18. [18] Challa-Malladi, M., Lieu, Y.K., Califano, O., Holmes, A.B., Bhagat, G., Murty, V.V., et al. Combined genetic inactivation of β2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 20 (2011), 728–740.
19. [19] Lanier, L.L., NK cell recognition. Annu Rev Immunol 23 (2005), 225–274.
20. [20] Bernd, H.-W., Ziepert, M., Thorns, C., Klapper, W., Wacker, H.-H., Hummel, M., et al. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma—analyses of cases from two prospective randomized clinical trials. Haematologica 94 (2009), 1569–1580.
21. [21] Roberts, R.A., Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 108 (2006), 311–318.
22. [22] Higashi, M., Tokuhira, M., Fujino, S., Yamashita, T., Abe, K., Arai, E., et al. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma. Leuk Lymphoma 57 (2016), 161–166.
23. [23] Rimsza, L.M., Farinha, P., Fuchs, D.A., Masoudi, H., Connors, J.M., Gascoyne, R.D., HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leuk Lymphoma 48 (2007), 542–546.
24. [24] Mottok, A., Steidl, C., Genomic alterations underlying immune privilege in malignant lymphomas. Curr Opin Hematol, 1, 2015.
25. [25] Riemersma, S.A., Jordanova, E.S., Schop, R.F., Philippo, K., Looijenga, L.H., Schuuring, E., et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 96 (2000), 3569–3577.
26. [26] Jordanova, E.S., Riemersma, S.A., Philippo, K., Giphart-Gassler, M., Schuuring, E., Kluin, P.M., Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer 35 (2002), 38–48.
27. [27] Rimsza, L.M., Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 107 (2005), 1101–1107.
28. [28] Green, M.R., Kihira, S., Liu, C.L., Nair, R.V., Salari, R., Gentles, A.J., et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci 112 (2015), E1116–E1125.
29. [29] Mottok, A., Woolcock, B., Chan, F.C., Tong, K.M., Chong, L., Farinha, P., et al. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep 13 (2015), 1418–1431.
30. [30] Steidl, C., Shah, S.P., Woolcock, B.W., Rui, L., Kawahara, M., Farinha, P., et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471 (2011), 377–381.
31. [31] Cycon, K.A., Rimsza, L.M., Murphy, S.P., Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL). Exp Hematol 37 (2009), 184–194.e2.
32. [32] Cycon, K.A., Mulvaney, K., Rimsza, L.M., Persky, D., Murphy, S.P., Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology 140 (2013), 259–272.
33. [33] God, J.M., Cameron, C., Figueroa, J., Amria, S., Hossain, A., Kempkes, B., et al. Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors. J Immunol 194 (2015), 1434–1445.
34. [34] Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (2002), 1937–1947.
35. [35] Rimsza, L.M., Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103 (2004), 4251–4258.
36. [36] Rodríguez, T., Méndez, R., Del Campo, A., Aptsiauri, N., Martín, J., Orozco, G., et al. Patterns of constitutive and IFN-γ inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics 59 (2007), 123–133.
37. [37] Van Vreeswijk, H., Ruiter, D., Bröcker, E., Welvaart, K., Ferrone, S., Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. J Invest Dermatol 90 (1988), 755–760.
38. [38] Johnson, D.B., Estrada, M.V., Salgado, R., Sanchez, V., Doxie, D.B., Opalenik, S.R., et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun, 7, 2016, 10582.
39. [39] Bernsen, M.R., Håkansson, L., Gustafsson, B., Krysander, L., Rettrup, B., Ruiter, D., et al. On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases. Br J Cancer 88 (2003), 424–431.
40. [40] Azimi, F., Scolyer, R.A., Rumcheva, P., Moncrieff, M., Murali, R., McCarthy, S.W., et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30 (2012), 2678–2683.
41. [41] Lee, N., Zakka, L.R., Mihm, M.C., Schatton, T., Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology (Phila) 48 (2016), 177–187.
42. [42] Colloby, P.S., West, K.P., Fletcher, A., Is poor prognosis really related to HLA-DR expression by malignant melanoma cells?. Histopathology 20 (1992), 411–416.
43. [43] Ricaniadis, N., Kataki, A., Agnantis, N., Androulakis, G., Karakousis, C.P., Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Eur J Surg Oncol EJSO 27 (2001), 88–93.
44. [44] Hersey, P., Si, Z., Smith, M.J., Thomas, W.D., Expression of the co-stimulatory molecule B7 on melanoma cells. Int J Cancer 58 (1994), 527–532.
45. [45] Guerry, D., Alexander, M.A., Herlyn, M.F., Zehngebot, L.M., Mitchell, K.F., Zmijewski, C.M., et al. HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J Clin Invest, 73, 1984, 267.
46. [46] Chen, L., Flies, D.B., Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13 (2013), 227–242.
47. [47] Demeure, C.E., Wolfers, J., Martin-Garcia, N., Gaulard, P., Triebel, F.T., Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell–cell contacts. Eur J Cancer 37 (2001), 1709–1718.
48. [48] Greaves, P., Gribben, J.G., The role of B7 family molecules in hematologic malignancy. Blood 121 (2013), 734–744.
49. [49] Stopeck, A.T., Gessner, A., Miller, T.P., Hersh, E.M., Johnson, C.S., Cui, H., et al. Loss of B7. 2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res 6 (2000), 3904–3909.
50. [50] Kanduri, M., Marincevic, M., Halldórsdóttir, A.M., Mansouri, L., Junevik, K., Ntoufa, S., et al. Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. Epigenetics 7 (2012), 1435–1442.
51. [51] Chang, C.-S., Chang, J.H., Hsu, N.C., Lin, H.-Y., Chung, C.-Y., Expression of CD80 and CD86 costimulatory molecules are potential markers for better survival in nasopharyngeal carcinoma. BMC Cancer [Internet], 7(88), 2007 [cited 2016 Jul 20]. Available from: http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-7-88.
52. [52] Koyama, S., Maruyama, T., Adachi, S., Nozue, M., Expression of costimulatory molecules, B7-1 and B7-2 on human gastric carcinoma. J Cancer Res Clin Oncol 124 (1998), 383–388.
53. [53] Denfeld, R.W., Dietrich, A., Wuttig, C., Tanczos, E., Weiss, J.M., Vanscheidt, W., et al. In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity. Int J Cancer 62 (1995), 259–265.
54. [54] Galluzzi, L., Vacchelli, E., Pedro, B.-S., Buqué, A., Senovilla, L., Baracco, E.E., et al. Classification of current anticancer immunotherapies. Oncotarget 5 (2015), 12472–12508.
55. [55] Tran Janco, J.M., Lamichhane, P., Karyampudi, L., Knutson, K.L., Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol 194 (2015), 2985–2991.
56. [56] Ostrand-Rosenberg, S., Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 6 (1994), 722–727.
57. [57] Tanaka, K., Isselbacher, K.J., Khoury, G., Jay, G., Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science, 1985, 228.
58. [58] Ostrand-Rosenberg, S., Takur, A., Clements, V., Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol, 1990, 4068–4071.
59. [59] Armstrong, T.D., Clements, V.K., Martin, B.K., Ting, J.P.-Y., Ostrand-Rosenberg, S., Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci 94 (1997), 6886–6891.
60. [60] Xu, M., Qiu, G., Jiang, Z., von Hofe, E., Humphreys, R.E., Genetic modulation of tumor antigen presentation. Trends in Biotechnol 18 (2000), 167–172.
61. [61] Thompson, J.A., Srivastava, M.K., Bosch, J.J., Clements, V.K., Ksander, B.R., Ostrand-Rosenberg, S., The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunol Immunother 57 (2008), 389–398.
62. [62] Chen, L., Ashe, S., Brady, W.A., Hellstrom, I., Hellstrom, K.E., Ledbetter, J.A., et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71 (1992), 1093–1102.
63. [63] Townsend, S.E., Allison, J.P., Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259 (1993), 368–370.
64. [64] Kaufman, H.L., Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 115 (2005), 1903–1912.
65. [65] Del Campo, A.B., Carretero, J., Munoz, J.A., Zinchenko, S., Ruiz-Cabello, F., Gonzalez-Aseguinolaza, G., et al. Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition. Cancer Gene Ther 21 (2014), 317–332.
66. [66] Chiriva-Internati, M., Grizzi, F., Pinkston, J., Morrow, K.J., D'Cunha, N., Frezza, E.E., et al. Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. Vitro Cell Dev Biol Anim 42 (2006), 89–95.
67. [67] Santin, A.D., Hiserodt, J.C., Fruehauf, J., DiSaia, P.J., Pecorelli, S., Granger, G.A., Effects of irradiation on the expression of surface antigens in human ovarian cancer. Gynecol Oncol 60 (1996), 468–474.
68. [68] Sharma, A., Bode, B., Wenger, R.H., Lehmann, K., Sartori, A.A., Moch, H., et al. γ-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One, 6, 2011, e28217.
69. [69] Santin, A.D., Hermonat, P.L., Hiserodt, J.C., Chiriva-Internati, M., Woodliff, J., Theus, J.W., et al. Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion costimulation molecules ICAM-1 in human cervical cancer. Int J Radiat Oncol Biol Phys 39 (1997), 737–742.
70. [70] Reits, E.A., Hodge, J.W., Herberts, C.A., Groothuis, T.A., Chakraborty, M., K.Wansley, E., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203 (2006), 1259–1271.
71. [71] Sharma, A., Bode, B., Studer, G., Moch, H., Okoniewski, M., Knuth, A., et al. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. Clin Cancer Res 19 (2013), 4843–4853.
72. [72] Lugade, A.A., Sorensen, E.W., Gerber, S.A., Moran, J.P., Frelinger, J.G., Lord, E.M., Radiation-induced IFN- production within the tumor microenvironment influences antitumor immunity. J Immunol 180 (2008), 3132–3139.
73. [73] Morel, A., Fernandez, N., de La Coste, A., Haddada, H., Viguier, M., Polla, B.S., et al. γ-Ray irradiation induces B7. 1 costimulatory molecule neoexpression in various murine tumor cells. Cancer Immunol Immunother 46 (1998), 277–282.
74. [74] Seo, A., Ishikawa, F., Nakano, H., Nakazaki, H., Kobayashi, K., Kakiuchi, T., Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation. Immunology 96 (1999), 642–648.
75. [75] Vereecque, R., Buffenoir, G., Gonzalez, R., Cambier, N., Hetuin, D., Bauters, F., et al. γ-Ray irradiation induces B7. 1 expression in myeloid leukaemic cells. Br J Haematol 108 (2000), 825–831.
76. [76] Sojka, D.K., Donepudi, M., Bluestone, J.A., Mokyr, M.B., Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol 164 (2000), 6230–6236.
77. [77] Murphy, S.P., Holtz, R., Lewandowski, N., Tomasi, T.B., Fuji, H., DNA alkylating agents alleviate silencing of class II transactivator gene expression in L1210 lymphoma cells. J Immunol 169 (2002), 3085–3093.
78. [78] De Biasi, A.R., Villena-Vargas, J., Adusumilli, P.S., Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 20 (2014), 5384–5391.
79. [79] Liu, W.M., Fowler, D.W., Smith, P., Dalgleish, A.G., Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 102 (2010), 115–123.
80. [80] Inoue, M., Mimura, K., Izawa, S., Shiraishi, K., Inoue, A., Shiba, S., et al. Expression of MHC class I on breast cancer cells correlates inversely with HER2 expression. OncoImmunology 1 (2012), 1104–1110.
81. [81] Maruyama, T., Mimura, K., Sato, E., Watanabe, M., Mizukami, Y., Kawaguchi, Y., et al. Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma. Br J Cancer 103 (2010), 552–559.
82. [82] Pollack, B.P., Sapkota, B., Cartee, T.V., Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res 17 (2011), 4400–4413.
83. [83] Dibb, N.J., Dilworth, S.M., Mol, C.D., Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 4 (2004), 718–727.
84. [84] Boni, A., Cogdill, A.P., Dang, P., Udayakumar, D., Njauw, C.-N.J., Sloss, C.M., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70 (2010), 5213–5219.
85. [85] Donia, M., Fagone, P., Nicoletti, F., Andersen, R.S., Høgdall, E., Straten, P., et al. BRAF inhibition improves tumor recognition by the immune system: potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. OncoImmunology 1 (2012), 1476–1483.
86. [86] Angell, T.E., Lechner, M.G., Jang, J.K., LoPresti, J.S., Epstein, A.L., MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res 20 (2014), 6034–6044.
87. V600E homozygous melanoma cells. OncoImmunology, 2, 2013, e22890.
88. [88] Liu, L., Mayes, P.A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 21 (2015), 1639–1651.
89. [89] Shen, L., Orillion, A., Pili, R., Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. Epigenomics 8 (2016), 415–428.
90. [90] Magner, W.J., Kazim, A.L., Stewart, C., Romano, M.A., Catalano, G., Grande, C., et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165 (2000), 7017–7024.
91. [91] Manning, J., Indrova, M., Lubyova, B., Pribylova, H., Bieblova, J., Hejnar, J., et al. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology 123 (2007), 218–227.
92. [92] Setiadi, A.F., Omilusik, K., David, M.D., Seipp, R.P., Hartikainen, J., Gopaul, R., et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 68 (2008), 9601–9607.
93. [93] Maeda, T., Towatari, M., Kosugi, H., Saito, H., Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96 (2000), 3847–3856.
94. [94] Puvvada, S.D., Li, H., Rimsza, L.M., Bernstein, S.H., Fisher, R.I., LeBlanc, M., et al. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma, 2016, 1–11.
95. [95] Atanackovic, D., Luetkens, T., Kloth, B., Fuchs, G., Cao, Y., Hildebrandt, Y., et al. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol 86 (2011), 918–922.
96. [96] Dubovsky, J.A., McNeel, D.G., Powers, J.J., Gordon, J., Sotomayor, E.M., Pinilla-Ibarz, J.A., Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res 15 (2009), 3406–3415.
97. [97] Coral, S., Sigalotti, L., Colizzi, F., Spessotto, A., Nardi, G., Cortini, E., et al. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J Cell Physiol 207 (2006), 58–66.
98. [98] Serrano, A., Tanzarella, S., Lionello, I., Mendez, R., Traversari, C., Ruiz-Cabello, F., et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2?-deoxycytidine treatment. Int J Cancer 94 (2001), 243–251.
99. [99] Morimoto, Y., Toyota, M., Satoh, A., Murai, M., Mita, H., Suzuki, H., et al. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-γ in haematopoietic tumour cells. Br J Cancer 90 (2004), 844–852.
100. [100] De Lerma Barbaro, A., De Ambrosis, A., Banelli, B., Pira, G.L., Aresu, O., Romani, M., et al. Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN- in promyelocytic cells. Int Immunol 20 (2008), 1457–1466.
101. [101] Li, H., Chiappinelli, K.B., Guzzetta, A.A., Easwaran, H., Yen, R.-W.C., Vatapalli, R., et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5 (2014), 587–598.
102. [102] Aue, G., Njuguna, N., Tian, X., Soto, S., Hughes, T., Vire, B., et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 94 (2009), 1266–1273.
103. [103] Andritsos, L.A., Johnson, A.J., Lozanski, G., Blum, W., Kefauver, C., Awan, F., et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 26 (2008), 2519–2525.
104. [104] Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M.J., Kroemer, G., Type I interferons in anticancer immunity. Nat Rev Immunol 15 (2015), 405–414.
105. [105] Parker, B.S., Rautela, J., Hertzog, P.J., Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 16 (2016), 131–144.
106. [106] Jonasch, E., Haluska, F.G., Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6 (2001), 34–55.
107. [107] Nagy, N., Vánky, F., Klein, E., Tumor surveillance: expression of the transporter associated with antigen processing (TAP-1) in ex-vivo human tumor samples and its elevation by in vitro treatment with IFN-γ and TNF-α. Immunol Lett 64 (1998), 153–160.
108. [108] Heise, R., Amann, P.M., Ensslen, S., Marquardt, Y., Czaja, K., Joussen, S., et al. Interferon alpha signalling and its relevance for the upregulatory effect of transporter proteins associated with antigen processing (TAP) in patients with malignant melanoma. PLoS One, 11, 2016, e0146325.
109. [109] Tamura, H., Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res 11 (2005), 5708–5717.
110. [110] Li, J., Yang, Y., Inoue, H., Mori, M., Akiyoshi, T., The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: its regulation by interferon γ and interleukin-10. Cancer Immunol Immunother 43 (1996), 213–219.
111. [111] Jahrsdörfer, B., Hartmann, G., Racila, E., Jackson, W., Mühlenhoff, L., Meinhardt, G., et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 69 (2001), 81–88.
112. [112] Weiner, G.J., CpG oligodeoxynucleotide-based therapy of lymphoid malignancies. Adv Drug Deliv Rev 61 (2009), 263–267.
113. [113] Li, J., Song, W., Czerwinski, D.K., Varghese, B., Uematsu, S., Akira, S., et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 179 (2007), 2493–2500.
114. [114] Houot, R., Levy, R., T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 113 (2009), 3546–3552.
115. [115] Brody, J.D., Ai, W.Z., Czerwinski, D.K., Torchia, J.A., Levy, M., Advani, R.H., et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 28 (2010), 4324–4332.
116. [116] Smits, E.L.J.M., Cools, N., Lion, E., Van Camp, K., Ponsaerts, P., Berneman, Z.N., et al. The toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol Immunother 59 (2010), 35–46.
117. [117] Zhong, R., Li, H., Messer, K., Lane, T.A., Zhou, J., Ball, E.D., Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by Toll-like receptor (TLR) agonists. Cancer Immunol Immunother 64 (2015), 737–744.
118. [118] Bevers, R.F.M., Kurth, K.-H., Schamhart, D.H.J., Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer [Internet] 91 (2004), 607–612 [cited 2016 Jul 28];Available from: http://www.nature.com/doifinder/10.1038/sj.bjc.6602026.
119. [119] Kobold, S., Wiedemann, G., Rothenfußer, S., Endres, S., Modes of action of TLR7 agonists in cancer therapy. Immunotherapy 6 (2014), 1085–1095.
120. [120] Alexandroff, A.B., Jackson, A.M., Paterson, T., Haley, J.L., Ross, J.A., Longo, D.L., et al. Role for CD40–CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 37 (2000), 515–526.
121. [121] Khong, A., Nelson, D.J., Nowak, A.K., Lake, R.A., Robinson, B.W.S., The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol 31 (2012), 246–266.
122. [122] Wennhold, K., Shimabukuro-Vornhagen, A., Theurich, S., von Bergwelt-Baildon, M., CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application. Expert Rev Vaccines 12 (2013), 631–637.
123. [123] Lapointe, R., Bellemare-Pelletier, A., Housseau, F., Thibodeau, J., Hwu, P., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 63 (2003), 2836–2843.
124. [124] Ahmadi, T., Flies, A., Efebera, Y., Sherr, D.H., CD40 ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology 124 (2008), 129–140.
125. [125] Chen, W., Yu, Y., Shao, C., Zhang, M., Wang, W., Zhang, L., et al. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody. Immunol Lett 77 (2001), 17–23.
126. [126] Trentin, L., Perin, A., Siviero, M., Piazza, F., Facco, M., Gurrieri, C., et al. B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation. Cancer 89 (2000), 1259–1268.
127. [127] Schultze, J.L., Cardoso, A.A., Freeman, G.J., Seamon, M.J., Daley, J., Pinkus, G.S., et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci 92 (1995), 8200–8204.
128. [128] Łuczyński, W., Kowalczuk, O., Iłendo, E., Stasiak-Barmuta, A., Krawczuk-Rybak, M., Upregulation of antigen-processing machinery components at mRNA level in acute lymphoblastic leukemia cells after CD40 stimulation. Ann Hematol 86 (2007), 339–345.
129. [129] Khanna, R., Cooper, L., Kienzle, N., Moss, D.J., Burrows, S.R., Khanna, K.K., Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol 159 (1997), 5782–5785.
130. [130] French, R.R., Chan, C., Tutt, A.L., Glennie, M., CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5 (1999), 548–553.
131. [131] Vonderheide, R.H., Butler, M.O., Liu, J.F., Battle, T.E., Hirano, N., Gribben, J.G., et al. CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity. Int J Oncol 19 (2001), 791–798.
132. [132] Von Leoprechting, A., van der Bruggen, P., Pahl, H.L., Aruffo, A., Simon, J.C., Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 59 (1999), 1287–1294.
133. [133] Hill, S.C., Youde, S.J., Man, S., Teale, G.R., Baxendale, A.J., Hislop, A., et al. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 174 (2005), 41–50.
134. [134] Ramsay, A.G., Clear, A.J., Fatah, R., Gribben, J.G., Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 120 (2012), 1412–1421.
135. [135] Ramsay, A.G., Johnson, A.J., Lee, A.M., Gorgün, G., Le Dieu, R., Blum, W., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest [Internet] 118:7 (2008), 2427–2437 [cited 2016 Mar 31];Available from: http://www.jci.org/articles/view/35017.
136. [136] Ramsay, A.G., Clear, A.J., Kelly, G., Fatah, R., Matthews, J., MacDougall, F., et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 114 (2009), 4713–4720.